Comparison of 4- and 24-hour intravenous infusion schedules for granulocyte-macrophage colony-stimulating factor

L. Wong, C. W. Taylor, E. Radwanski, Evan M Hersh, S. E. Salmon

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We evaluated the toxicity, pharmacokinetics, and biologic activity of 4- versus 24-h intravenous infusions of recombinant human granulocyte-macrophage colony-stimulating factor (rhuGM-CSF) in patients with advanced malignancy. The doses of rhuGM-CSF evaluated were 1, 3, 5, and 10 μg/kg administered by 4- or 24-h infusion for 10 days. A total of 32 patients was treated (17, 4-h infusion; 15, 24-h infusion). Toxicities seen with both schedules included fever, chills, nausea, emesis, fatigue, and pain. Other observations in the 4-h infusion group included pulmonary edema and bone pain and in the 24-h infusion group, leukocytosis and atrial fibrillation. Pharmacokinetic data for the 4-h infusion showed C(max) and area under the curve (AUC) increased with dose, and the terminal elimination half-life varied from 0.7 to 1.1 h. Comparative pharmacokinetic assessment of the 24-h infusion was difficult because of low steady-state plasma concentrations. Hematologic effects in the 24-h infusion group included a dose-dependent increase in total white blood cells and absolute granulocyte count, generally greater than those in the 4- h infusion group. In summary, a greater biologic effect occurred in the 24-h infusion group than in the 4-h infusion group. The toxicity profile differed slightly between the 4- and 24-h infusion groups, but both were generally well tolerated by patients.

Original languageEnglish (US)
Pages (from-to)57-65
Number of pages9
JournalJournal of Immunotherapy
Volume18
Issue number1
StatePublished - 1995

Fingerprint

Granulocyte-Macrophage Colony-Stimulating Factor
Intravenous Infusions
Appointments and Schedules
Pharmacokinetics
Pain
Chills
Leukocytosis
Pulmonary Edema
Granulocytes
Atrial Fibrillation
Nausea
Area Under Curve
Vomiting
Fatigue
Half-Life
Leukocytes
Fever
Bone and Bones
Neoplasms

Keywords

  • Biologic effect
  • Pharmacokinetics
  • Recombinant human granulocyte-macrophage colony-stimulating factor
  • Toxicity

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Pharmacology

Cite this

Comparison of 4- and 24-hour intravenous infusion schedules for granulocyte-macrophage colony-stimulating factor. / Wong, L.; Taylor, C. W.; Radwanski, E.; Hersh, Evan M; Salmon, S. E.

In: Journal of Immunotherapy, Vol. 18, No. 1, 1995, p. 57-65.

Research output: Contribution to journalArticle

@article{d5f794941e384ce69dd88a21874f82c3,
title = "Comparison of 4- and 24-hour intravenous infusion schedules for granulocyte-macrophage colony-stimulating factor",
abstract = "We evaluated the toxicity, pharmacokinetics, and biologic activity of 4- versus 24-h intravenous infusions of recombinant human granulocyte-macrophage colony-stimulating factor (rhuGM-CSF) in patients with advanced malignancy. The doses of rhuGM-CSF evaluated were 1, 3, 5, and 10 μg/kg administered by 4- or 24-h infusion for 10 days. A total of 32 patients was treated (17, 4-h infusion; 15, 24-h infusion). Toxicities seen with both schedules included fever, chills, nausea, emesis, fatigue, and pain. Other observations in the 4-h infusion group included pulmonary edema and bone pain and in the 24-h infusion group, leukocytosis and atrial fibrillation. Pharmacokinetic data for the 4-h infusion showed C(max) and area under the curve (AUC) increased with dose, and the terminal elimination half-life varied from 0.7 to 1.1 h. Comparative pharmacokinetic assessment of the 24-h infusion was difficult because of low steady-state plasma concentrations. Hematologic effects in the 24-h infusion group included a dose-dependent increase in total white blood cells and absolute granulocyte count, generally greater than those in the 4- h infusion group. In summary, a greater biologic effect occurred in the 24-h infusion group than in the 4-h infusion group. The toxicity profile differed slightly between the 4- and 24-h infusion groups, but both were generally well tolerated by patients.",
keywords = "Biologic effect, Pharmacokinetics, Recombinant human granulocyte-macrophage colony-stimulating factor, Toxicity",
author = "L. Wong and Taylor, {C. W.} and E. Radwanski and Hersh, {Evan M} and Salmon, {S. E.}",
year = "1995",
language = "English (US)",
volume = "18",
pages = "57--65",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Comparison of 4- and 24-hour intravenous infusion schedules for granulocyte-macrophage colony-stimulating factor

AU - Wong, L.

AU - Taylor, C. W.

AU - Radwanski, E.

AU - Hersh, Evan M

AU - Salmon, S. E.

PY - 1995

Y1 - 1995

N2 - We evaluated the toxicity, pharmacokinetics, and biologic activity of 4- versus 24-h intravenous infusions of recombinant human granulocyte-macrophage colony-stimulating factor (rhuGM-CSF) in patients with advanced malignancy. The doses of rhuGM-CSF evaluated were 1, 3, 5, and 10 μg/kg administered by 4- or 24-h infusion for 10 days. A total of 32 patients was treated (17, 4-h infusion; 15, 24-h infusion). Toxicities seen with both schedules included fever, chills, nausea, emesis, fatigue, and pain. Other observations in the 4-h infusion group included pulmonary edema and bone pain and in the 24-h infusion group, leukocytosis and atrial fibrillation. Pharmacokinetic data for the 4-h infusion showed C(max) and area under the curve (AUC) increased with dose, and the terminal elimination half-life varied from 0.7 to 1.1 h. Comparative pharmacokinetic assessment of the 24-h infusion was difficult because of low steady-state plasma concentrations. Hematologic effects in the 24-h infusion group included a dose-dependent increase in total white blood cells and absolute granulocyte count, generally greater than those in the 4- h infusion group. In summary, a greater biologic effect occurred in the 24-h infusion group than in the 4-h infusion group. The toxicity profile differed slightly between the 4- and 24-h infusion groups, but both were generally well tolerated by patients.

AB - We evaluated the toxicity, pharmacokinetics, and biologic activity of 4- versus 24-h intravenous infusions of recombinant human granulocyte-macrophage colony-stimulating factor (rhuGM-CSF) in patients with advanced malignancy. The doses of rhuGM-CSF evaluated were 1, 3, 5, and 10 μg/kg administered by 4- or 24-h infusion for 10 days. A total of 32 patients was treated (17, 4-h infusion; 15, 24-h infusion). Toxicities seen with both schedules included fever, chills, nausea, emesis, fatigue, and pain. Other observations in the 4-h infusion group included pulmonary edema and bone pain and in the 24-h infusion group, leukocytosis and atrial fibrillation. Pharmacokinetic data for the 4-h infusion showed C(max) and area under the curve (AUC) increased with dose, and the terminal elimination half-life varied from 0.7 to 1.1 h. Comparative pharmacokinetic assessment of the 24-h infusion was difficult because of low steady-state plasma concentrations. Hematologic effects in the 24-h infusion group included a dose-dependent increase in total white blood cells and absolute granulocyte count, generally greater than those in the 4- h infusion group. In summary, a greater biologic effect occurred in the 24-h infusion group than in the 4-h infusion group. The toxicity profile differed slightly between the 4- and 24-h infusion groups, but both were generally well tolerated by patients.

KW - Biologic effect

KW - Pharmacokinetics

KW - Recombinant human granulocyte-macrophage colony-stimulating factor

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=0029088820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029088820&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 57

EP - 65

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 1

ER -